Drugs / ABBV-2B04
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04644120 | Dec 2020 → Aug 2021 | COVID-19 | AbbVie | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ABBV-2B04 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04644120 ↗ |
| Modality | Monoclonal antibody | “ABBV-47D11 and ABBV-2B04 are investigational anti-SARS-CoV-2 monoclonal antibodies” NCT04644120 ↗ |